Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports

被引：1

作者：

Osone, Shinya ^{[1
]}

Imamura, Toshihiko ^{[1
]}

Kanayama, Takuyo ^{[1
,2
]}

Tsuma, Yusuke ^{[1
]}

Kawashima-Goto, Sachiko ^{[1
]}

Nakatani, Takuya ^{[1
]}

Sugimoto, Atsuya ^{[1
]}

Takai, Akari ^{[1
]}

Miyachi, Mitsuru ^{[1
]}

Tamura, Shinichi ^{[2
]}

Ishida, Hiroyuki ^{[1
,2
]}

Hosoi, Hajime ^{[1
]}

机构：

[1] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kyoto, Japan

[2] Matsushita Mem Hosp, Dept Pediat, Moriguchi, Osaka, Japan

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2017年 / 39卷 / 04期

关键词：

acute myeloid leukemia; sorafenib; FLT3-ITD; stem cell transplantation; children; STEM-CELL TRANSPLANTATION; MULTIKINASE INHIBITOR SORAFENIB; COMBINATION; CYTARABINE; RELAPSE; HLA;

D O I：

10.1097/MPH.0000000000000672

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sorafenib is a promising agent for treating pediatric refractory acute myeloid leukemia (AML) exhibiting FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD); however, its optimal use needs to be established. We report 2 cases of refractory pediatric FLT3-ITD-positive AML treated with sorafenib. Case 1 underwent stem cell transplantation (SCT) without entering remission, despite the use of chemotherapy. This patient relapsed despite receiving post-SCT sorafenib. Chemotherapy combined with sorafenib successfully achieved complete remission in case 2. This patient received post-SCT sorafenib and remains in complete remission. The combination of pre-SCT and post-SCT sorafenib may thus be effective for pediatric refractory FLT3-ITD-positive AML.

引用

页码：E199 / E202

页数：4

共 14 条

[1] Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia
Baker, Sharyn D.
Zimmerman, Eric I.
Wang, Yong-Dong
Orwick, Shelley
Zatechka, Douglas S.
Buaboonnam, Jassada
Neale, Geoffrey A.
Olsen, Scott R.
Enemark, Eric J.
Shurtleff, Sheila
Rubnitz, Jeffrey E.
Mullighan, Charles G.
Inaba, Hiroto
[J]. CLINICAL CANCER RESEARCH, 2013, 19 (20) : 5758 - 5768
[2] Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
Chen, Yi-Bin
Li, Shuli
Lane, Andrew A.
Connolly, Christine
Del Rio, Candice
Valles, Betsy
Curtis, Morgan
Ballen, Karen
Cutler, Corey
Dey, Bimalangshu R.
El-Jawahri, Areej
Fathi, Amir T.
Ho, Vincent T.
Joyce, Amy
McAfee, Steven
Rudek, Michelle
Rajkhowa, Trivikram
Verselis, Sigitas
Antin, Joseph H.
Spitzer, Thomas R.
Levis, Mark
Soiffer, Robert
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (12) : 2042 - 2048
[3] FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
Grunwald, Michael R.
Levis, Mark J.
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (06) : 683 - 694
[4] Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia
Hu, Shuiying
Niu, Hongmei
Inaba, Hiroto
Orwick, Shelley
Rose, Charles
Panetta, John C.
Yang, Shengping
Pounds, Stanley
Fan, Yiping
Calabrese, Christopher
Rehg, Jerold E.
Campana, Dario
Rubnitz, Jeffrey E.
Baker, Sharyn D.
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (11) : 893 - 905
[5] Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia
Inaba, Hiroto
Rubnitz, Jeffrey E.
Coustan-Smith, Elaine
Li, Lie
Furmanski, Brian D.
Mascara, Gerard P.
Heym, Kenneth M.
Christensen, Robbin
Onciu, Mihaela
Shurtleff, Sheila A.
Pounds, Stanley B.
Pui, Ching-Hon
Ribeiro, Raul C.
Campana, Dario
Baker, Sharyn D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3293 - 3300
[6] In vitro studies of a FM inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
Levis, M
Pham, R
Smith, BD
Small, D
[J]. BLOOD, 2004, 104 (04) : 1145 - 1150
[7] MRD detection of leukemia relapse using HLA typing by FACS in combination with FISH after mismatched allogeneic stem cell transplantation
Miyachi, Mitsuru
Watanabe, Eri
Watanabe, Nobukazu
Tsuma, Yusuke
Kawashima-Goto, Sachiko
Tamura, Shinichi
Imamura, Toshihiko
Ishida, Hiroyuki
Hosoi, Hajime
[J]. PEDIATRIC TRANSPLANTATION, 2014, 18 (05) : E180 - E184
[8] A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
Pratz, K. W.
Cho, E.
Levis, M. J.
Karp, J. E.
Gore, S. D.
McDevitt, M.
Stine, A.
Zhao, M.
Baker, S. D.
Carducci, M. A.
Wright, J. J.
Rudek, M. A.
Smith, B. D.
[J]. LEUKEMIA, 2010, 24 (08) : 1437 - 1444
[9] Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Ravandi, Farhad
Cortes, Jorge E.
Jones, Daniel
Faderl, Stefan
Garcia-Manero, Guillermo
Konopleva, Marina Y.
O'Brien, Susan
Estrov, Zeev
Borthakur, Gautam
Thomas, Deborah
Pierce, Sherry R.
Brandt, Mark
Byrd, Anna
Bekele, B. Nebiyou
Pratz, Keith
Luthra, Rajyalakshmi
Levis, Mark
Andreeff, Michael
Kantarjian, Hagop M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1856 - 1862
[10] Sorafenib Treatment Following Hematopoietic Stem Cell Transplant in Pediatric FLT3/ITD Acute Myeloid Leukemia
Tarlock, Katherine
Chang, Bill
Cooper, Todd
Gross, Thomas
Gupta, Sumit
Neudorf, Steven
Adlard, Kathleen
Ho, Phoenix A.
McGoldrick, Suzanne
Watt, Tanya
Templeman, Tina
Sisler, India
Garee, Amy
Thomson, Blythe
Woolfrey, Ann
Estey, Elihu
Meshinchi, Soheil
Pollard, Jessica A.
[J]. PEDIATRIC BLOOD & CANCER, 2015, 62 (06) : 1048 - 1054

← 1 2 →